PURPOSE: The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. MATERIALS AND METHODS: The original systematic review and meta-analysis of the published literature yielded 303 studies published from 1996 through 2013. This review informed the majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence. In April 2014, the CRPC guideline underwent amendment based on an additional literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. In March 2015, the CRPC guideline underwent a second amendment, which incorporated 10 additional studies into the evidence base published through February 2015. RESULTS: Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements for multiple index patients. CONCLUSIONS: Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. This guideline will be continually updated as new literature emerges in the field.
PURPOSE: The purpose of this amendment is to incorporate relevant newly-published literature to better provide a rational basis for the management of patients with castration-resistant prostate cancer. MATERIALS AND METHODS: The original systematic review and meta-analysis of the published literature yielded 303 studies published from 1996 through 2013. This review informed the majority of the guideline statements. Clinical Principles and Expert Opinions were used for guideline statements lacking sufficient evidence. In April 2014, the CRPC guideline underwent amendment based on an additional literature search, which retrieved additional studies published between February 2013 and February 2014. Thirty-seven studies from this search provided data relevant to the specific treatment modalities for CRPC. In March 2015, the CRPC guideline underwent a second amendment, which incorporated 10 additional studies into the evidence base published through February 2015. RESULTS: Guideline statements based on six index patients developed to represent the most common scenarios encountered in clinical practice were amended appropriately. The additional literature provided the basis for an update of current supporting text as well as the incorporation of new guideline statements for multiple index patients. CONCLUSIONS: Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of the individual patient's treatment goals. Patients' preferences and personal goals should be considered when choosing management strategies. This guideline will be continually updated as new literature emerges in the field.
Authors: Megan E V Caram; Samuel R Kaufman; Parth K Modi; Lindsey Herrel; Mary Oerline; Ryan Ross; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian Journal: Urology Date: 2019-05-25 Impact factor: 2.649
Authors: Brandon L Ellsworth; Allan K Metz; Nicole M Mott; Ruby Kazemi; Michael Stover; Tasha Hughes; Lesly A Dossett Journal: Ann Surg Oncol Date: 2022-02-06 Impact factor: 5.344
Authors: Megan E V Caram; Shikun Wang; Phoebe Tsao; Jennifer J Griggs; David C Miller; Brent K Hollenbeck; Paul Lin; Bhramar Mukherjee Journal: Urol Pract Date: 2019-07-01
Authors: Douglas G McNeel; Neil H Bander; Tomasz M Beer; Charles G Drake; Lawrence Fong; Stacey Harrelson; Philip W Kantoff; Ravi A Madan; William K Oh; David J Peace; Daniel P Petrylak; Hank Porterfield; Oliver Sartor; Neal D Shore; Susan F Slovin; Mark N Stein; Johannes Vieweg; James L Gulley Journal: J Immunother Cancer Date: 2016-12-20 Impact factor: 13.751